Ziftomenib: A Novel Menin Inhibitor Targeting Molecular Pathways in Acute Myeloid Leukemia & Its Regulatory Consideration's

Resumen

Ziftomenib is a novel, selective oral menin inhibitor developed for the treatment of acute myeloid leukemia (AML), particularly in molecular subtypes characterized by NPM1 mutations and KMT2A rearrangements. This review summarizes its pharmacological properties, mechanism of action, experimental evidence, and emerging clinical data. Ziftomenib exerts its anti-leukemic effects by disrupting the menin–KMT2A interaction, leading to downregulation of leukemogenic transcriptional programs such as HOXA9 and MEIS1, and promoting differentiation of leukemic blasts.

Preclinical studies, including in vitro and in vivo models, demonstrate significant inhibition of leukemic cell proliferation and restoration of normal hematopoietic processes. Early-phase clinical trials in relapsed or refractory AML patients have shown promising efficacy, with meaningful remission rates and a manageable safety profile. Its oral bioavailability and targeted mechanism provide advantages over conventional chemotherapy.

However, challenges such as potential resistance mechanisms, safety concerns, and limited long-term clinical data remain. Overall, ziftomenib represents a promising targeted therapeutic strategy, with further studies needed to optimize its clinical application and expand its role in AML management.